Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott McCallister

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Eclinicalmedicine|May 27, 2021
Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled TrialAndrea R Thurman, Jill L Schwartz, Mackenzie L Cottrell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2020
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS StudyJenna Yager, Jose Castillo-Mancilla, Mustafa E Ibrahim, et al.
Annals of Epidemiology|April 28, 2020
Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018Aaron J Siegler, C Christina Mehta, Farah Mouhanna, et al.
Clinical Trials (London, England)|February 6, 2023
Demographic diversity of US-based participants in GSK-sponsored interventional clinical trialsMichel M Reid, Scott P Davis, Ouzama N Henry, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissuesMackenzie L Cottrell, Katy L Garrett, Heather M A Prince, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2006
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trialJoseph Gathe, David A Cooper, Charles Farthing, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2024
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEPKelong Han, Parul Patel, Scott McCallister, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
Ebiomedicine|October 16, 2016
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir AlafenamideNicholas T Funderburg, Grace A McComsey, Manjusha Kulkarni, et al.
Annals of Internal Medicine|May 21, 2013
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trialMark S Sulkowski, Kenneth E Sherman, Douglas T Dieterich, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Eclinicalmedicine|May 27, 2021
Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled TrialAndrea R Thurman, Jill L Schwartz, Mackenzie L Cottrell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2020
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS StudyJenna Yager, Jose Castillo-Mancilla, Mustafa E Ibrahim, et al.
Annals of Epidemiology|April 28, 2020
Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018Aaron J Siegler, C Christina Mehta, Farah Mouhanna, et al.
Clinical Trials (London, England)|February 6, 2023
Demographic diversity of US-based participants in GSK-sponsored interventional clinical trialsMichel M Reid, Scott P Davis, Ouzama N Henry, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissuesMackenzie L Cottrell, Katy L Garrett, Heather M A Prince, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2006
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trialJoseph Gathe, David A Cooper, Charles Farthing, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2024
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEPKelong Han, Parul Patel, Scott McCallister, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
Ebiomedicine|October 16, 2016
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir AlafenamideNicholas T Funderburg, Grace A McComsey, Manjusha Kulkarni, et al.
Annals of Internal Medicine|May 21, 2013
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trialMark S Sulkowski, Kenneth E Sherman, Douglas T Dieterich, et al.
Pageof 4